A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol
BMC Psychiatry June 2, 2020 J. Phillips, N. Jaworska, Elizabeth Kamler et al. 22 citations
A multi-centre trial across four Canadian institutions will compare intravenous ketamine infusions with electroconvulsive therapy (ECT) for treating major depressive episodes in 240 patients with major depressive or bipolar disorder. Patients are randomized to either ECT or ketamine three times per week for three to four weeks; non-responders cross over to the other treatment. Responders enter a six-month maintenance phase. The primary outcome is change in depression severity scores assessed by blinded raters. The study aims to identify clinical, molecular, and imaging predictors of response to each treatment.